0002102720 1 2026-05-15 2026-05-15 0002102720 2 2026-05-15 2026-05-15 0002102720 3 2026-05-15 2026-05-15 0002102720 4 2026-05-15 2026-05-15 0002102720 5 2026-05-15 2026-05-15 0002102720 6 2026-05-15 2026-05-15 0002102720 2026-05-15 2026-05-15 iso4217:USD pure F-1/A EX-FILING FEES 0002102720 333-295210 N/A N/A F-1 Tarsier Pharma Ltd. false Equity Ordinary shares, par value NIS 0.01 per share true 17250000.00 0.0001381 2382.23 false Equity Representative's warrants to purchase ordinary shares true 0.00 0.0001381 0.00 false Equity Ordinary shares issuable upon exercise of the Representative's Warrants true 694312.00 0.0001381 95.88 true Equity Ordinary shares, par value NIS 0.01 per share true 34500000.00 4764.45 true Equity Representative's warrants to purchase ordinary shares true 0.00 true Equity Ordinary shares issuable upon exercise of the Representative's Warrants true 1388625.00 191.77 53832937.00 7434.33 4956.22 0.00 2478.11 Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price. Includes ordinary shares that may be issued upon exercise of a 45-day option granted to the underwriters in this offering to cover over-allotments, if any. Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price. No fee required pursuant to Rule 457(g). Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price. We have agreed to issue to the representative of the underwriters warrants (the “Representative’s Warrants”) to purchase up to 3.5% of the ordinary shares sold in this offering at 115% of the public offering price per share. Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price Includes ordinary shares that may be issued upon exercise of a 45-day option granted to the underwriters in this offering to cover over-allotments, if any. Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price No fee required pursuant to Rule 457(g). Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price We have agreed to issue to the representative of the underwriters warrants (the “Representative’s Warrants”) to purchase up to 3.5% of the ordinary shares sold in this offering at 115% of the public offering price per share.